Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty
Authors not listed
TNF Pharmaceuticals, Inc. · 2022
Abstract
The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Anonymous. (2022). A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty. <em>TNF Pharmaceuticals, Inc.</em>. https://clinicaltrials.gov/study/NCT05283486
Vancouver
Anonymous. A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty. TNF Pharmaceuticals, Inc.. 2022.
BibTeX
@misc{anon2022ADoubl,
title = {A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty},
author = {Anonymous},
journal = {TNF Pharmaceuticals, Inc.},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
PubMed 2018
Preprint
[Aging-related frailty and sarcopenia. The relationship between "inflammaging" and frailty/sarcopenia.]
SciNeuro 2023
Open access · US-GOV
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SNP318 in Healthy Adult Participants
BioAge Labs, Inc. 2021
Open access · US-GOV
A Phase 2a, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging
Regeneron Pharmaceuticals 2013
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia
Advances in experimental medicine and biology 2020
Citation only
Inflammation, Frailty and Cardiovascular Disease
Neurotrope Bioscience, Inc. 2020
Open access · US-GOV